Glaukos Corporation (GKOS)
NYSE: GKOS · Real-Time Price · USD
144.01
+1.86 (1.31%)
May 15, 2026, 4:00 PM EDT - Market closed
Glaukos Revenue
Glaukos had revenue of $150.57M in the quarter ending March 31, 2026, with 41.16% growth. This brings the company's revenue in the last twelve months to $551.35M, up 36.30% year-over-year. In the year 2025, Glaukos had annual revenue of $507.44M with 32.33% growth.
Revenue (ttm)
$551.35M
Revenue Growth
+36.30%
P/S Ratio
15.14
Revenue / Employee
$503,975
Employees
1,094
Market Cap
8.45B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 507.44M | 123.96M | 32.33% |
| Dec 31, 2024 | 383.48M | 68.77M | 21.85% |
| Dec 31, 2023 | 314.71M | 31.85M | 11.26% |
| Dec 31, 2022 | 282.86M | -11.15M | -3.79% |
| Dec 31, 2021 | 294.01M | 69.05M | 30.70% |
| Dec 31, 2020 | 224.96M | -12.03M | -5.07% |
| Dec 31, 2019 | 236.98M | 55.71M | 30.73% |
| Dec 31, 2018 | 181.28M | 22.02M | 13.83% |
| Dec 31, 2017 | 159.25M | 44.86M | 39.21% |
| Dec 31, 2016 | 114.40M | 42.70M | 59.55% |
| Dec 31, 2015 | 71.70M | 26.11M | 57.28% |
| Dec 31, 2014 | 45.59M | 24.64M | 117.64% |
| Dec 31, 2013 | 20.95M | 18.52M | 762.33% |
| Dec 31, 2012 | 2.43M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zimmer Biomet Holdings | 8.41B |
| Smith & Nephew | 6.16B |
| Bruker | 3.46B |
| Globus Medical | 3.10B |
| Insulet | 2.90B |
| Bio-Rad Laboratories | 2.59B |
| Bio-Rad Laboratories | 2.59B |
| Masimo | 1.56B |
GKOS News
- 4 days ago - Glaukos Announces Participation in Upcoming Investor Conferences - Business Wire
- 15 days ago - Glaukos price target raised to $153 from $134 at Goldman Sachs - TheFly
- 15 days ago - Glaukos price target raised to $170 from $160 at Stifel - TheFly
- 15 days ago - Glaukos price target raised to $140 from $120 at JPMorgan - TheFly
- 15 days ago - Glaukos price target raised to $136 from $127 at Needham - TheFly
- 15 days ago - Glaukos price target raised to $141 from $131 at BTIG - TheFly
- 15 days ago - Glaukos price target raised to $140 from $135 at Citi - TheFly
- 16 days ago - Glaukos reports Q1 EPS (18c), consensus (28c) - TheFly